<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526966</url>
  </required_header>
  <id_info>
    <org_study_id>1108060</org_study_id>
    <secondary_id>2011-A00860-41</secondary_id>
    <nct_id>NCT02526966</nct_id>
  </id_info>
  <brief_title>Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy</brief_title>
  <acronym>NIGA-RA</acronym>
  <official_title>Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a
      prognostic value (which could increase the risk of Renal Absolute), the longitudinal
      monitoring for these antibodies could be of interest: (1) in the monitoring of patients (in
      place including a possible repetition renal biopsy); (2) to guide treatment decisions and (3)
      in clinical research, as an outcome (in substitution for the occurrence of kidney failure) in
      therapeutic trials IgA nephropathy.

      This research project constitutes the first step in validating these antibodies biomarker of
      IgA nephropathy and its main objective is to study the performance of the blood levels of
      anti-hinge region antibodies in the diagnosis of progressive forms of histologically IgA
      nephropathy as defined by the Renal Risk Absolute.

      The secondary objectives of this project are to establish a bio-collection that will allow us
      to search for other prognostic factors (genetic, cellular and serum) of IgA nephropathy and
      to evaluate the performance of Renal Absolute risk by integrating Oxford score, the new
      international histological classification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">June 30, 2014</completion_date>
  <primary_completion_date type="Actual">June 30, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum concentration of anti-hinge region antibodies (mg/ml)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>patient with primitive form of IgA nephropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>dosage of anti-hinge region antibodies</description>
    <arm_group_label>patient with primitive form of IgA nephropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major Patient

          -  Diagnosis of a primitive form of IgA nephropathy histologically proven

        Exclusion Criteria:

          -  Suspicion of secondary IgA nephropathy forms

          -  Less than 5 glomeruli present on renal biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH d'ANNECY</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'ANNONAY</name>
      <address>
        <city>Annonay</city>
        <zip>07100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de BOURG EN BRESSE</name>
      <address>
        <city>Bourg En Bresse</city>
        <zip>01000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de CHAMBERY</name>
      <address>
        <city>Chambery</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de CLERMONT-FERRAND</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard. HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du PUY EN VELAY</name>
      <address>
        <city>Puy En Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de ROANNE</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Drome Nord</name>
      <address>
        <city>Romans</city>
        <zip>26100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de VALENCE</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du TONKIN</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

